MyC Revenue and Competitors
Estimated Revenue & Valuation
- MyC's estimated annual revenue is currently $2.6M per year.
- MyC's estimated revenue per employee is $98,000
Employee Data
- MyC has 27 Employees.
- MyC grew their employee count by 17% last year.
MyC's People
| Name | Title | Email/Phone |
|---|
MyC Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $14.3M | 102 | 12% | N/A | N/A |
#2 | $6.7M | 53 | -10% | N/A | N/A |
#3 | $17.4M | 124 | -2% | N/A | N/A |
#4 | $4M | 38 | 6% | $15.5M | N/A |
#5 | $18.2M | 130 | -8% | $34.5M | N/A |
#6 | $8.8M | 70 | -18% | N/A | N/A |
#7 | $9.5M | 75 | N/A | N/A | N/A |
#8 | $4.4M | 39 | N/A | N/A | N/A |
#9 | $1.4M | 17 | N/A | N/A | N/A |
#10 | $1M | 12 | N/A | N/A | N/A |
What Is MyC?
Developing top-notch tech solutions for healthcare workers to manage and take care of their patients. By creating extensive usage on the field, MyC modules gather tremendous data for companies to manage their healthcare risks and control their financial impact.
keywords:N/A
N/A
Total Funding
27
Number of Employees
$2.6M
Revenue (est)
17%
Employee Growth %
N/A
Valuation
N/A
Accelerator
MyC News
2022-04-13 - Co-expression patterns explain how a basic transcriptional role for MYC
modulates Wnt and MAPK pathways in colon and lung adenocarcinomas
Co-expression patterns explain how a basic transcriptional role for MYC modulates Wnt and MAPK pathways in colon and lung adenocarcinomas.
2022-04-06 - Monte Rosa Therapeutics Presents Preclinical Data Highlighting Potential of
GSPT1-directed Molecular Glue Degrader MRT-2359 to Target Myc-driven
Cancers at AACR Annual Meeting 2022
Data Highlight Essential Role of GSPT1 in Sustaining Myc-induced Translational Addiction in Solid Tumors .
2022-04-06 - Omega Therapeutics Presents Preclinical Data on OTX-2002, First-in-Class
Epigenomic Controller, as Potential Treatment for Hepatocellular Carcinoma
at the AACR Annual Meeting 2022
OTX-2002 suppresses c-Myc gene expression resulting in a loss of cancer cell viability in vitro and reduces tumor growth in in vivo...
Other Companies in Paris
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $2.6M | 27 | -16% | N/A |
#2 | $4.7M | 27 | -4% | N/A |
#3 | $2.6M | 27 | N/A | N/A |
#4 | $2.7M | 27 | N/A | N/A |
#5 | $2.7M | 27 | -7% | N/A |